Search clinical trials for: GDC-1971

Total 467 results

Genentech, Inc.

Completed

Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer

Breast Cancer

Belgium, United States
Revolution Medicines, Inc.
Sanofi

Completed

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Solid Tumor

United States, Korea, Republic of
AbbVie

Active, not recruiting

Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma (MCL)

Japan
Ohio State University Comprehensive Cancer Center

Active, not recruiting

Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations

Chronic Lymphocytic Leukemia | Ibrutinib Resistance

United States
Philipps University Marburg Medical Center

Completed

CDRM Study: Computer-assisted Diabetes Risk Management-for Secondary and Tertiary Prevention of T2DM Complications (CDRM_DMP)

Diabetes Mellitus Type 2

Germany
National Institute of Allergy and Infectious Diseases...

Completed

The Safety and Effectiveness of Injections of Human Recombinant Interferon-gamma in Patients With AIDS Who Have Taken Zidovudine

HIV Infections

United States
Boston Scientific Corporation
EKOS Corporation

Completed

Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism (OPTALYSE PE)

Pulmonary Embolism and Thrombosis

United States, United Kingdom
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma

Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIA Cutaneous Melanoma...

United States
M.D. Anderson Cancer Center
Kura Oncology, Inc.

Not yet recruiting

A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University; American Association for... and other collaborators

Recruiting

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma

United States
National Cancer Institute (NCI)

Terminated

Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer

Prostate Adenocarcinoma | Stage IIA Prostate Cancer AJCC v7 | Stage IIB Prostate Cancer AJCC v7

United States
Georgetown University
Hackensack Meridian Health

Active, not recruiting

A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL

Chronic Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center

Recruiting

Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010)

Leukemia, Lymphocytic, Chronic, B-Cell | Lymphoma, Small Lymphocytic | CLL | SLL | Small-Cell Lymphoma | Leukemia, Chronic Lymphocytic

Italy, Argentina, Chile, Israel, South Africa, United States, Australia, Puerto Rico, Spain, Canada, Germany, France, United Kingdom, Colombia, Belgium, Brazil
The First Affiliated Hospital of Soochow University

Recruiting

AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission

Acute Myeloid Leukemia (AML) in Remission

China
AbbVie

Active, not recruiting

A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) (VIALE-T)

Cancer | Acute Myeloid Leukemia (AML)

United States, Australia, Brazil, Canada, China, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Spain, Switzerland, Taiwan, United Kingdom
National Cancer Institute (NCI)

Completed

A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage

Extensive Stage Small Cell Lung Carcinoma | Recurrent Small Cell Lung Carcinoma

United States
Hoffmann-La Roche
AbbVie; German CLL Study Group

Active, not recruiting

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Lymphocytic Leukemia, Chronic

United States, Spain, France, United Kingdom, Australia, Canada, Denmark, Germany, Italy, Brazil, Argentina, Estonia, New Zealand, Austria, Bulgaria, Croatia, Romania, Russian Federation, Poland, Switzerland, Mexico
University of California, San Francisco
National Institute of Neurological Disorders and Stroke (NINDS); The Chad-Tough... and other collaborators

Recruiting

Combination Therapy for the Treatment of Diffuse Midline Gliomas

Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | Recurrent Diffuse Intrinsic Pontine Glioma | Recurrent Diffuse Midline Glioma, H3 K27M-Mutant | Recurrent WHO Grade III Glioma | WHO Grade III Glioma

United States, Netherlands, Israel, Australia, New Zealand, Switzerland
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Neoadjuvant Treatment Modalities in Esophageal Cancer

Esophageal Cancer | Chemoradiation | Surgery | Chemotherapy Effect | Immunotherapy | Targeted Therapy | Esophagogastric Juction Cancer

China
Teva Pharmaceuticals USA

Completed

600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fed Conditions

Healthy

Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor

Refractory Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Shandong Cancer Hospital and Institute

Unknown

A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma

Prosthesis Survival

China
AbbVie

Completed

A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies

Cancer | Advanced Solid Tumors | Hematologic Malignancies

United States, Japan, Netherlands, Spain
Genentech, Inc.

Completed

Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy

Metastatic Breast Cancer

United States
Genentech, Inc.

Completed

A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors

Solid Cancers

United States, Spain
M.D. Anderson Cancer Center
Astex Pharmaceuticals, Inc.

Suspended

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States
AbbVie

Completed

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
M.D. Anderson Cancer Center
HiberCell, Inc.

Recruiting

Phase I Study of HC-7366 With Azacitidine and Venetoclax for Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Genentech, Inc.
Breast International Group; SOLTI Breast Cancer Research Group; Austrian Breast...

Completed

A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)

Breast Cancer

United States, United Kingdom, Germany, Australia, Austria, Belgium, Brazil, France, Guatemala, Italy, Korea, Republic of, Panama, Poland, Portugal, Spain, Czechia, Hungary, Mexico, Peru, Switzerland, El Salvador, Chile
Genentech, Inc.

Completed

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

Malignant Melanoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Genentech, Inc.; Celgene Corporation; Stand Up To Cancer

Completed

Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas

Metastatic Pancreatic Cancer

United States
MedSIR
Hoffmann-La Roche

Completed

Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer (PATHFINDER)

Triple Negative Breast Cancer

Spain, Portugal
Genentech, Inc.

Completed

A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer

Breast Cancer

Belgium, United States, Italy
AbbVie
Genentech, Inc.

Completed

A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia

AML | Acute Myelogenous Leukemia

United States, Australia, Germany, Italy
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer

Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer

United States
M.D. Anderson Cancer Center
Syros Pharmaceuticals Inc.

Withdrawn

Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia

United States
Hoffmann-La Roche
AbbVie

Completed

A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (MURANO)

Chronic Lymphocytic Leukemia

Hungary, Spain, France, United Kingdom, United States, Australia, Austria, Belgium, Canada, Czechia, Denmark, Germany, Italy, Korea, Republic of, Netherlands, New Zealand, Poland, Russian Federation, Sweden, Taiwan
M.D. Anderson Cancer Center
Qurient Co., Ltd.

Not yet recruiting

Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Hoffmann-La Roche

Terminated

A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread

Breast Cancer

Israel, Italy, Spain, United States, Belgium, Czechia, Australia, United Kingdom, Korea, Republic of, Romania, France, Taiwan, Latvia
Brian Druker
AbbVie; Oregon Health and Science University; Incyte Corporation

Active, not recruiting

Ruxolitinib and Venetoclax in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
Kura Oncology, Inc.

Not yet recruiting

A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias

Refractory Acute Leukemia | Pediatric Relapsed

United States
M.D. Anderson Cancer Center

Recruiting

A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

Acute Myeloid Leukemia

United States
Hoffmann-La Roche

Terminated

A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer (IPATunity150)

Breast Cancer

United States, Brazil, Australia, Canada, Japan, Korea, Republic of, Spain, United Kingdom
AbbVie

Active, not recruiting

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

Japan
MedSIR

Recruiting

Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10% (EMPRESS)

Breast Cancer | Breast Cancer, Early-Onset

Spain, France
Jean-Luc Van Laethem
Roche Pharma AG

Unknown

Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer (NEOPACHI-001)

Pancreatic Adenocarcinoma Resectable

Belgium
AbbVie
Roche-Genentech

Completed

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

Chronic Lymphocytic Leukemia

United States
Hoffmann-La Roche
AbbVie

Completed

A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)

Follicular Lymphoma

United States, Italy, Canada, Australia, Belgium, United Kingdom, Germany, France
Emory University
National Cancer Institute (NCI); Genentech, Inc.; National Institutes of Health...

Active, not recruiting

Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma | CCND1 Positive | t(11;14) Positive

United States

Search clinical trials for: GDC-1971

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Norway

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations